Careers  |  Sign In  |  Register

Biologic Therapy for Rheumatoid Arthritis Linked to Possible Risk of Malignancies

A new report in The Journal of the American Medical Association assessed “the risk of malignancy in patients with rheumatoid arthritis (RA) enrolled in randomized controlled trials (RCTs) of biologic response modifiers (BRMs). “The study compared the “safety of any BRMs used in RA patients with placebo and/or any traditional disease-modifying anti-rheumatic drugs with a minimum of 24 weeks of follow-up.” The research indicated that the use of BRMs “… was not significantly associated with an increased risk of malignancy compared with other disease-modifying antirheumatic drugs or with placebo.”

Read it in The Journal of the American Medical Association.